ライフサイエンスコーパス: preventive treatment

1 ronary endothelial function as the basis for preventive treatment.

2 in guidelines and recommended for targeting preventive treatment.

3 o benefit from early spectacle correction or preventive treatment.

4 arly marker of preclinical CAD for potential preventive treatment.

5 ased headache frequency is an indication for preventive treatment.

6 Patients with VB events require active preventive treatment.

7 culosis control by more precise targeting of preventive treatment.

8 ad hepatotoxic reactions to isoniazid during preventive treatment.

9 y-two percent of PMP women were receiving no preventive treatment.

10 re inadequate and there is limited access to preventive treatment.

11 r disease, which is a missed opportunity for preventive treatment.

12 e sulfadoxine-pyrimethamine for intermittent preventive treatment.

13 nfection suggest an enormous opportunity for preventive treatment.

14 r active tuberculosis were offered isoniazid preventive treatment.

15 re born to mothers who received intermittent preventive treatment.

16 M-CSF showed neuroprotective effects as a preventive treatment.

17 ing the costs of disease against that of the preventive treatment.

18 ed with the highest coverage of intermittent preventive treatment.

19 ic higher risk group potentially amenable to preventive treatments.

20 periods and may be useful for initiation of preventive treatments.

21 ven when used in addition to other secondary preventive treatments.

22 evelop epilepsy and which might benefit from preventive treatments.

23 psychosis and more effective and potentially preventive treatments.

24 ies the possibility of new targets for broad preventive treatments.

25 ascular Risk Using SIGN Guidelines to Assign Preventive Treatment]).

26 sessed the efficacy of seasonal intermittent preventive treatment-a full dose of antimalarial treatme

27 The month of onset of preventive treatment action was assessed.

28 to sulfadoxine-pyrimethamine as intermittent preventive treatment against malaria in pregnancy (IPTp)

29 during intervention, and usual intermittent preventive treatment against malaria was given.

30 ights have enormous potential for developing preventive treatments against bacterial infections.

31 This would aid the design of preventive treatments against the rapid decline of CD4(+

32 tance dispersal, but combining curative with preventive treatments ahead of the front reduced local d

33 These new advances in preventive treatment and a better understanding of its r

34 seen in two of 24 countries for intermittent preventive treatment and in three of 30 countries for in

35 Although coverage of intermittent preventive treatment and use of insecticide-treated nets

36 ors associated with coverage of intermittent preventive treatment and use of insecticide-treated nets

37 0 years in association with increased use of preventive treatments and major reductions in premorbid

38 multi-disease campaign, offering diagnostic, preventive, treatment and referral services, was perform

39 ed changes in invasive coronary angiography, preventive treatments, and clinical outcomes using natio

40 diagnosis on invasive coronary angiography, preventive treatments, and clinical outcomes.

41 Early diagnosis and preventive treatment are instrumental to prevent sudden

42 rlying arterial pathology, risk factors, and preventive treatments, but they are rarely studied concu

43 ed on admission into the Early Diagnosis and Preventive Treatment Clinic, an outpatient clinic specia

44 Intermittent preventive treatment could be highly effective for preve

45 studies suggest that urgent use of existing preventive treatments could reduce the risk by 80-90%, b

46 rt of diagnosing osteoporosis and deciding a preventive treatment course.

47 Preventive treatment decreases migraine frequency and im

48 emoglobin concentration, use of intermittent preventive treatment during pregnancy (IPTp) for malaria

49 Intermittent preventive treatment during pregnancy (IPTp) with sulfad

50 Intermittent preventive treatment during pregnancy (IPTp) with sulfad

51 Intermittent preventive treatment during pregnancy with SP may contin

52 Preventive treatment effectively lowers the risk of dise

53 ly Vitamin A has proven a safe and effective preventive treatment for BPD.

54 spirin is a common, chronically administered preventive treatment for cardiovascular disease, but is

55 inued development of the laser as a possible preventive treatment for caries.

56 y is warranted of tuberculosis screening and preventive treatment for children at high-risk of this d

57 Fremanezumab as a preventive treatment for chronic migraine resulted in a

58 Intermittent preventive treatment for malaria during infancy (IPTi) i

59 co-trimoxazole prophylaxis and intermittent preventive treatment for malaria in pregnant women (IPTp

60 long-lasting insecticidal nets, intermittent preventive treatment for malaria, regular anthelmintic d

61 Although evidence for estrogen as a preventive treatment for menstrual migraine is inconsist

62 d peptide (CGRP), is being investigated as a preventive treatment for migraine.

63 There is no preventive treatment for patients at risk.

64 Step I diet, statin therapy, and no preventive treatment for primary and secondary preventio

65 No preventive treatment for this disease is available.

66 ts and pulmonary biologists have long sought preventive treatments for bronchopulmonary dysplasia (BP

67 The benefits of screening and preventive treatments for individuals with cancer-relate

68 d stroke, risk factors, and premorbid use of preventive treatments from 1981-84 (Oxford Community Str

69 to better understand etiology, mechanism and preventive treatments going forward.

70 Significant benefits for the OT preventive treatment group were found across various hea

71 nical trials have documented the efficacy of preventive treatment in asymptomatic women.

72 prevention, previously known as intermittent preventive treatment in children, is highly effective in

73 Intermittent preventive treatment in infants (IPTi) is a new malaria

74 Intermittent preventive treatment in infants (IPTi) is the administra

75 trial in Tanzania suggest that intermittent preventive treatment in infants (IPTi), delivered throug

76 thamine at times of vaccination-intermittent preventive treatment in infants (IPTi)-is a promising st

77 e fraction of recipients, while intermittent preventive treatment in infants provides modest partial

78 women in sub-Saharan Africa of intermittent preventive treatment in pregnancy (IPTp) and insecticide

79 In a recent trial of intermittent preventive treatment in pregnancy (IPTp) in Uganda, dihy

80 Intermittent preventive treatment in pregnancy (IPTp) is used to prev

81 Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxin

82 continues to be recommended for intermittent preventive treatment in pregnancy (IPTp).

83 ke incidence, major risk factors, and use of preventive treatments in an ageing population are requir

84 estimates for 2007, coverage of intermittent preventive treatment increased from 13.1% (11.9-14.3) to

85 TB case finding, treatment of TB, isoniazid preventive treatment, infection control, administration

86 aimed to review the coverage of intermittent preventive treatment, insecticide-treated nets, and ante

87 heart disease (CHD) risk assessment to guide preventive treatment intensity.

88 Intermittent preventive treatment (IPT) for malaria is used in infant

89 We examined the effect of intermittent preventive treatment (IPT) in reducing anaemia and impro

90 Intermittent preventive treatment (IPT) in schoolchildren offers a pr

91 Intermittent preventive treatment (IPT) of malaria has recently been

92 ) is used throughout Africa for intermittent preventive treatment (IPT) of malaria, but resistance th

93 s study was to find out whether intermittent preventive treatment (IPT) with a fixed-dose combination

94 enrollment, followed by either intermittent preventive treatment (IPT) with SP at 4 and 8 weeks and

95 Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethami

96 with sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP) on malaria risk in HIV-pos

97 hree daily doses of amodiaquine intermittent preventive treatment (IPTi) or placebo.

98 ategy for sub-Saharan Africa of intermittent-preventive-treatment (IPTp) with two doses of sulphadoxi

99 roke, and what evidence there is that urgent preventive treatment is likely to be effective in reduci

100 Three general strategies emerge: global preventive treatment, local treatment within a neighborh

101 h-transmission regions (such as intermittent preventive treatment) may require further evaluation; ap

102 opment of neuroimaging surrogate markers and preventive treatments might eventually lead to so-called

103 ished, especially since early diagnostic and preventive-treatment modalities are limited.

104 These compounds are good candidates for the preventive treatment of cataract, age-related macular de

105 the further development of TEV-48125 for the preventive treatment of chronic migraine in a phase 3 tr

106 125, a monoclonal anti-CGRP antibody, in the preventive treatment of chronic migraine.

107 125, a monoclonal anti-CGRP antibody, in the preventive treatment of high-frequency episodic migraine

108 was safe, well tolerated, and effective as a preventive treatment of high-frequency episodic migraine

109 Preventive treatment of LTBI resulted in a 1.8-fold aver

110 fadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp).

111 Intermittent preventive treatment of malaria during pregnancy (IPTp)

112 changed its recommendation for intermittent preventive treatment of malaria during pregnancy (IPTp)

113 Intermittent preventive treatment of malaria in children (IPTc) is a

114 008-2009, as well as a trial of intermittent preventive treatment of malaria in infants in Navrongo,

115 the continuing low coverage of intermittent preventive treatment of malaria in pregnancy (IPTp).

116 y evidence for the efficacy of ALD403 in the preventive treatment of migraine in patients with a high

117 onin gene-related peptide antibodies for the preventive treatment of migraine.

118 We found that preventive treatment of Tg2576 mice with valsartan signi

119 aling as an attractive target for developing preventive treatments of epilepsy in humans.

120 scular risk may be used for the targeting of preventive treatments of individual patients who are asy

121 le-blind trial of the effect of intermittent preventive treatment on morbidity from malaria in three

122 comes associated with CTE and for developing preventive treatment programs.

123 existing international guidelines, possible preventive treatments, rationales for different manageme

124 ting to childhood stroke; however, acute and preventive treatment recommendations are based on interv

125 retroviral treatment coverage, and effective preventive treatment regimens.

126 In sensitivity analyses, coverage of primary preventive treatments remained cost-effective even if ad

127 We propose that preventive treatment should pay more attention to molecu

128 Coverage of intermittent preventive treatment showed greater inequity overall tha

129 diate-term outcome measure for evaluation of preventive treatment strategies.

130 ymptomatic diagnosis and could lead to early preventive treatment strategies.

131 have shown a conclusive benefit of a single preventive treatment strategy.

132 ated, and urban women more likely to receive preventive treatment than their poorer, uneducated, rura

133 ne bone density testing and to have received preventive treatments than were patients of other specia

134 Preventive treatment that reduces CVD by even a small pe

135 depends on a relative cost of palliative and preventive treatment, the details of the local strategy

136 lying epileptogenesis and discover potential preventive treatments, the lack of PIE biomarkers hinder

137 value for the development and evaluation of preventive treatment therapies.

138 e future, genetic testing may allow specific preventive treatments to be delivered to individuals at

139 After 4 weeks of preventive treatment, tumors formed in 12.5, 50, and 100

140 Preventive treatment use did not differ significantly.

141 infection risk were modified by intermittent preventive treatment use.

142 2009-11 to estimate coverage of intermittent preventive treatment, use of insecticide-treated nets, a

143 ong pregnant women who received intermittent preventive treatment using sulfadoxine-pyrimethamine (IP

144 Preventive treatment using TCSs of various potencies, ad

145 In Liberia during the wet season, malaria preventive treatment was cost saving even when average d

146 of WHO's 2012 policy update for intermittent preventive treatment, which aims to simplify the message

147 Our findings suggest that effective preventive treatments will need to eliminate these small

148 Preventive treatment with an antibody that sequesters ne

149 The association between SES and secondary preventive treatment with antiplatelet and statin medica

150 this study was to determine whether systemic preventive treatment with Aspirin-triggered RvD1 (AT-RvD

151 ent girls or women who received intermittent preventive treatment with dihydroartemisinin-piperaquine

152 with sulfadoxine-pyrimethamine, intermittent preventive treatment with dihydroartemisinin-piperaquine

153 on at delivery was lower in the intermittent preventive treatment with dihydroartemisinin-piperaquine

154 hich were least frequent in the intermittent preventive treatment with dihydroartemisinin-piperaquine

155 dihydroartemisinin-piperaquine, intermittent preventive treatment with dihydroartemisinin-piperaquine

156 droartemisinin-piperaquine, and intermittent preventive treatment with dihydroartemisinin-piperaquine

157 lity, and cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine

158 rtemisinin-piperaquine (n=515), intermittent preventive treatment with dihydroartemisinin-piperaquine

159 Taken together, these data indicate that preventive treatment with paquinimod ameliorates experim

160 th weight among women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT

161 misinin-piperaquine (n=516), or intermittent preventive treatment with sulfadoxine-pyrimethamine (n=5

162 n-piperaquine group than in the intermittent preventive treatment with sulfadoxine-pyrimethamine grou

163 s not a suitable alternative to intermittent preventive treatment with sulfadoxine-pyrimethamine in t

164 The effectiveness of the intermittent preventive treatment with sulfadoxine-pyrimethamine stra

165 Compared with intermittent preventive treatment with sulfadoxine-pyrimethamine, int

166 ydroartemisinin-piperaquine, or intermittent preventive treatment with sulfadoxine-pyrimethamine.

167 Delivery of intermittent preventive treatment with sulphadoxine-pyrimethamine to

168 which aims to simplify the message and align preventive treatment with the focused antenatal care sch

169 Here, we show that preventive treatment with the Q compound paquinimod (ABR

170 d prevention strategies include intermittent preventive treatment with two doses of sulfadoxine-pyrim